Effects of the Bowman-Birk protease inhibitor on survival of fibroblasts and cancer cells exposed to radiation and cis-platinum.
The Bowman-Birk inhibitor (BBI) is a soybean-derived anticarcinogenic protease inhibitor with anti-inflammatory activity. To assess the possibility of utilizing BBI for alleviating the side effects associated with lung cancer radiation and chemotherapy, we have determined the effects of BBI and a soybean concentrate enriched in BBI (known as BBIC) on radiation- and cis-platinum-induced cytotoxicity in A549 human lung cancer cells. The results demonstrated that neither BBI nor BBIC protected A549 cells from radiation- and cis-platinum-induced cytotoxicity. In fact, BBI and BBIC potentiated the cell-killing effects induced by cis-platinum alone, and BBIC treatment led to significantly enhanced cell killing by cis-platinum in combination with radiation treatment in the lung carcinoma cells. BBI conferred a significant protective effect onto mouse fibroblasts (10T1/2 cells) treated with cis-platinum in combination with 6 Gy of X-ray irradiation. These results suggest that BBI and BBIC, when given to lung cancer patients, are unlikely to interfere with cancer treatment utilizing radiation and cis-platinum.
Kennedy
C W
CW
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.
Donahue
J J
JJ
Wan
X S
XS
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects*; D002945:Cisplatin / Q000627:therapeutic use*; D004357:Drug Synergism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D051379:Mice; D014358:Trypsin Inhibitor, Bowman-Birk Soybean / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D014358:Trypsin Inhibitor, Bowman-Birk Soybean; D002945:Cisplatin